In xenograft mouse models of HER2-positive breast cancer implanted with BT-474 cells, tucatinib treatment resulted in a delay in tumor growth comparable to trastuzumab monotherapy, and these effects were enhanced in the combination therapy of tucatinib plus trastuzumab [73]. Here, ERBB2 is linked to breast cancer.